Enveric Biosciences (ENVB) announced a second notice of allowance from the USPTO for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. The allowed patent application, titled “Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,” covers a series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
- Psychedelic: Clearmind expands trial for Alcohol Use Disorder
- Enveric Biosciences announces results of EB-003 preclinical model
- Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
- Enveric announces data broadening clinical potential for lead candidate
- Psychedelic: Clearmind engages government, political affairs consulting firm